Ryerson (RYZ) Q1 2026 Earnings Transcript

Ryerson posted first-quarter net sales of $1.57 billion, up 37.9% year over year, with adjusted EBITDA ex-LIFO rising to $67.4 million from $32.8 million and same-store revenue up 17.1% sequentially. Management guided Q2 revenue to $1.86 billion-$1.93 billion and adjusted EBITDA ex-LIFO to $88 million-$92 million, while highlighting early Olympic Steel synergies, a new $100 million buyback authorization, and improving transactional demand. Leverage increased to 5.1x after the acquisition, but liquidity improved to $618 million and the company expects synergy capture and EBITDA growth to reduce debt ratios over time.

Analysis

The cleanest read-through is that the merger is turning Ryerson into a more volatile but potentially much more levered operating surrogate for industrial PMI. The mix shift toward transactional business matters because it monetizes price/availability dislocations faster than contract revenue, so the company is now structurally more exposed to near-term commodity inflation and freight tightness, but also better positioned to capture margin when inventories are lean and lead times shorten. That creates a favorable setup for the next 1-2 quarters if the current order inflection persists, yet it also means the earnings step-up is more fragile than the headline revenue growth suggests.

The bigger second-order effect is balance-sheet optics versus balance-sheet reality. Leverage will likely compress mechanically as EBITDA rolls up and synergies flow through, but the buyback authorization adds a pro-cyclical capital return overlay that could become a liability if metal prices re-accelerate and working capital re-inflates. In other words, the equity can rerate on EBITDA growth, but the credit story is still hostage to inventory discipline and the pace of cash conversion over the next 90-180 days.

The most important contrarian point is that consensus may be underestimating how much of the near-term upside is already in the print, while underappreciating how much of the medium-term upside depends on OEM cyclicals that are still soft. The market is likely to reward the synergy narrative first and the contract recovery later; if the second half fails to broaden beyond transactional strength, the stock can stall even with stable earnings. For competitors, the improved Ryerson footprint should pressure smaller service centers lacking scale in same-day delivery and procurement, while the likely winner from integration is not just Ryerson but any upstream supplier with exposure to a more efficient, higher-turn inventory system.

Key Decisions for Investors

• Long RYI outright for 1-2 quarters: best risk/reward is a momentum trade on synergy realization and transactional mix expansion, with upside if Q2/Q3 EBITDA beats while leverage visibly falls.
• Pair trade: long RYI / short ZEUS over the next 3-6 months. RYI has a clearer earnings bridge from merger synergies and working-capital normalization; ZEUS is more exposed to a slower, more cyclical metals tape without the same integration catalyst.
• Buy RYI call spreads into the next print (3-5 month tenor) rather than stock if available premium is reasonable. The catalyst path is front-loaded, but the buyback/leverage debate caps multiple expansion if the macro stalls.
• Fade aggressive chase after any post-earnings gap-up unless contract volumes visibly improve. The trade is strongest while the market is paying for synergies; once that is priced, the stock becomes more dependent on OEM recovery, which is a slower-moving catalyst.
• Watch for a credit-sensitive hedge: if RYI rallies hard and leverage stays above ~4x longer than expected, consider trimming equity longs and hedging with industrial cyclicals exposure, as the market can quickly reprice the balance-sheet risk.